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(SLEDAI)Abstract Background: Systemic lupus erythematosus (SLE) is an autoimmune disease character-
ized by the production of auto-antibodies leading to a spectrum of clinical ﬁndings. Among these
auto-antibodies are anti-chromatin and anti-histone antibodies in which researches showed a
renewed interest in the last few years.
Aim of the work: The aim of our study was to assess the serum levels of anti-chromatin and anti-
histone antibodies in patients with SLE, and to correlate them with clinical features of the disease.
Patients and methods: The study included 60 female SLE patients and 13 normal females as con-
trols. Patients were subjected to full history taking, clinical examination, and laboratory tests.
Serum anti-chromatin and anti-histone antibodies were detected using enzyme linked immunosor-
bent assay (ELISA) in patients and controls.
Results: Anti-chromatin antibodies showed 100% sensitivity and 66.7% speciﬁcity, while anti-
histone antibodies showed 100% sensitivity and 53.3% speciﬁcity. A statistically signiﬁcant differ-
ence was elicited between SLE patients and controls regarding the serum levels of both antibodies.
Serum levels of anti-chromatin antibodies in SLE patients were signiﬁcantly correlated with the
occurrence of hematological manifestations, duration of steroid therapy, and also dose and dura-
tion of hydroxychloroquine (HCQ) therapy. However, no signiﬁcant correlation was found between
anti-histone antibodies and other parameters.
98 S.M. El Desouky et al.Conclusion: Anti-chromatin and anti-histone antibodies are both sensitive and speciﬁc for SLE
and can be used not only for its diagnosis, but also for following therapeutic progress. Further stud-
ies on a large scale are needed to elucidate the effect of therapy on the serum levels of these anti-
bodies in SLE patients.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Systemic Lupus Erythematosus (SLE) is often described as the
classical systemic autoimmune disease due to its wide spectrum
of clinical and immunological abnormalities [1]. It is the most
diverse of the autoimmune diseases and it is characterized by
the production of multiple auto-antibodies with a complex
and wide spectrum [2,3]. Even though the presence of autoan-
tibodies in SLE has been known, for more than 60 years, still
nowadays a great effort is being made to understand the
pathogenetic, diagnostic, and prognostic meaning of such
autoantibodies [3]. The prominent feature of immunological
defects in SLE is the production of autoantibodies to nuclear
antigens including deoxyribonucleic acid (DNA), histones
and ribonucleoprotein (RNP) [4].
Anti-double stranded DNA (anti-dsDNA) antibodies are
considered useful for the diagnosis of SLE, to monitor the dis-
ease activity, and correlate with renal and central nervous
involvements [3]; they are found only in 50% of SLE patients
and do not always correlate with disease activity [5].
On the other hand, antinuclear antibodies (ANA), the most
prevalent antibodies, have low speciﬁcity for the diagnosis of
SLE because they are found in most systemic autoimmune dis-
eases and even in healthy individuals. Thus, it is important to
look for other auto-antibodies that may be useful in the diag-
nosis and assessment of the disease activity in SLE patients [6].
Autoantibodies directed to chromatin components date
back to the discovery of the LE cell with subsequent evidence
that major components were chromatin and histones in par-
ticular. Over time, immunoassays ranging from ELISA and
line immunoassays to more modern bead-based assays incor-
porated histone and DNA mixtures, puriﬁed histones, and
puriﬁed nucleosomes leading to a more thorough understand-
ing of the genesis and pathogenetic relationships of antibodies
to chromatin components in SLE and other autoimmune con-
ditions [7]. Anti-nucleosome antibodies are an excellent marker
for SLE and good predictors of ﬂares in quiescent lupus and
anti-histone antibodies characterize drug-induced lupus [3].
Methods to detect anti-nucleosome antibodies have been
available for more than 10 years and the test has demonstrated
its good sensitivity and high speciﬁcity in diagnosing SLE.
Despite these data produced through clinical and laboratory
research, the test is little used. Data from the metanalysis have
shown that anti-nucleosome antibodies have equal speciﬁcity
but higher sensitivity and prognostic value than anti-dsDNA
antibodies in the diagnosis of SLE. The use of anti-nucleosome
antibodies appears more efﬁcacious than anti-dsDNA [8].
Anti-histones were associated with a higher proportion of pro-
liferative renal disease and poorer outcome in lupus nephritis
patients [9].
The aim of the present study was to assess the serum levels
of anti-chromatin and anti-histone antibodies in SLE patientsand to correlate their serum levels with various clinical features
of SLE.
2. Patients and methods
2.1. Patients
The present study was carried out on 60 SLE patients fulﬁlling
the 1982 American College of Rheumatology (ACR) revised
criteria for the classiﬁcation of SLE [10,11] in addition to 13
apparently healthy age and sex matched subjects as the control
group. All patients were selected from the outpatient clinic of
Rheumatology and Rehabilitation Department, Cairo Univer-
sity Hospitals. An Informed consent was obtained from all
participants in the study, and the study was approved by the
Institutional Review Board (IRB) of faculty of medicine, Cairo
University.
2.2. Methods
All patients have been subjected to:
1. Comprehensive history taking and thorough clinical examina-
tion: general, cardiopulmonary, abdominal, neurological
and musculoskeletal system.
2. Routine laboratory investigations: complete blood count
(CBC), erythrocyte sedimentation rate (ESR), liver and kid-
ney functions and urine analysis, in addition to estimation
of total albumin in 24 h urine, blood glucose, immuno-
logical assays as anti-nuclear antibodies (ANA), anti-dou-
ble strand DNA (anti-dsDNA) antibodies, anti Ro, anti
La, anticardiolipin (aCL) antibodies and serum comple-
ment levels (C3 and C4).
3. Assessment of disease activity using Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI): Grading of dis-
ease activity to mild (1–10), moderate (11–20), severe (21–
45), and very severe (>45) [12]. A ﬁnal weight total SLE-
DAI score is then calculated with possible theoretic score
of 105 [13].
4. Radiological Investigations: X-ray for any affected joint and
Chest X-ray for detection of chest problems as pleural effu-
sion, or interstitial lung disease.
5. Electrocardiography (ECG): for detection of ischemia,
pericardial effusion, valvular abnormalities, pericarditis,
myocarditis or endocarditis.
6. Renal biopsy and histopathological assessment in cases with
renal involvement.
Serum anti-chromatin and anti-histone antibodies were
detected in patients and controls as follows:
Determination of serum anti-chromatin (anti-nucleosome)
and anti-histone antibodies using QUANTA-lite chromatin
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(ELISA) for the semi quantitative detection of chromatin anti-
bodies and histone antibodies in human serum.
Principle: Highly puriﬁed total histones and anti-chromatin
are bound to microwells. Antibodies to these antigens, if pre-
sent in diluted serum, bind in the microwells. Washing of the
microwells removes unbound serum antibodies. Horseradish
peroxidase (HRP) conjugated anti-human IgG immuno-
logically binds to the bound patient antibodies forming a con-
jugate/antibody/antigen complex. Washing of the microwells
removes unbound conjugate. An enzyme substrate in the pres-
ence of bound conjugate hydrolyzes to form a blue color. The
addition of an acid stops the reaction forming a yellow end-
product. The intensity of this yellow color is measured photo-
metrically at 450 nm. The amount of color is directly propor-
tional to the concentration of IgG antibodies present in the
original sample.
Specimen collection, storage and handling:Whole blood spe-
cimens were collected using acceptable medical techniques to
avoid hemolysis, then blood is allowed to clot and the serum
is separated by centrifugation. Tested serum should be clear
and non-hemolyzed. Specimens could be refrigerated at 2–
8 C for up to ﬁve days or stored at 20 C up to six months.
Repetitive freezing and thawing of serum samples should be
avoided as it may result in variable loss of autoantibody activ-
ity. Also, testing of heat-inactivated sera is not recommended.
Quality control: This test is only valid if the optical density
at 450 nm for Positive Control (1) and Negative Control (2) as
well as for the Calibrators A and F complies with the respec-
tive range indicated on the Quality Control Certiﬁcate
enclosed to each test kit. If any of these criteria is not met,
the results are invalid and the test should be repeated.
Calculation of results: For anti-histone, anti-histone IgG a
4-Parameter-Fit with lin-log coordinates for optical density
and concentration is the data reduction method of choice.
Smoothed Spline Approximation and log–log coordinates are
also suitable.
Interpretation of results: In a normal range study with
serum samples from healthy blood donors the following ranges
have been established with:
- The anti-histone test: anti-histone IgG, Cut-Off: 7.1 U/ml.
- The anti-nucleosome test: anti-nucleosome IgG, Cut-Off:
37.5 U/ml.
Data were statistically described in terms of mean ± stan-
dard deviation (SD), range (minimum–maximum), and per-
centage. Comparison between cases and control groups was
done using Student’s t test for independent samples. Correla-
tion between various variables was done using Pearson
moment correlation equation for linear relation in normally
distributed variables and Spearman rank correlation equation
for non-normal variables. p Values less than 0.05 was consid-
ered statistically signiﬁcant. All statistical calculations were
done using computer programs SPSS version 13 (Statistical
Package for the Social Science; SPSS Inc., Chicago, IL, USA).3. Results
The present study included 60 SLE female patients (Group A)
as diagnosed according to the American College of Rheuma-tology (ACR) revised criteria for the classiﬁcation of SLE with
a mean age of 29.3 ± 7.5 years (age range 17–50 years). In
addition, an age-matched group of 13 healthy females were
included as the control group (Group B), with a mean age of
32 ± 6.4 years (age range from 22 to 48 years). The descriptive
data of SLE Patients (Group A) are shown in Table 1.
The mean level of anti-chromatin antibodies (U/ml) in
group A (SLE patients) was 103.02 ± 23.6 (38.1–142.5), eluci-
dating a statistically signiﬁcant difference as compared to
39.7 ± 18.4 (18.9–82.1) in group B (controls) (p< 0.001)
(Fig. 1). Regarding anti-histone antibodies (U/ml), its mean
level in SLE patients (Group A) was 17.8 ± 7.2 (7.4–42.1),
as compared to 7.7 ± 3.4 (2.1–12.8) in group B (controls),
which once again shows a statistically signiﬁcant difference
(p< 0.001) (Fig. 1).
On comparing between the mean levels of anti-chromatin
and anti-histone antibodies among Group A (SLE patients)
with different clinical manifestations, a statistically signiﬁcant
difference was found between the levels of anti-chromatin anti-
bodies with hematological manifestations as compared to
those without (p= 0.01) (Table 2). On comparing between
the mean levels of anti-chromatin and anti-histone antibodies
among Group A (SLE patients) with different variables, a sta-
tistically signiﬁcant negative correlation was elucidated
between the levels of anti-chromatin antibodies with the hemo-
globin concentration (r= 0.39, p= 0.002) (Table 3).
Regarding drug intake, a statistically signiﬁcant negative
correlation was elucidated between anti-chromatin antibodies’
level and the duration of steroid therapy (r= 0.26,
p= 0.04), as well as with the hydroxychloroquine (HCQ) ther-
apy regarding both dose (r= 0.29, p= 0.037), and duration
(r= 0.28, p= 0.049) (Table 3).
Among Group A, 48 patients (80%) had lupus nephritis
and 42 of them (70%) performed renal biopsy for grading of
renal involvement. On comparing between serum levels of both
anti-chromatin and anti-histone antibodies among patients
with various grades of renal involvement, the highest mean
level of anti-chromatin antibodies was in patients with grade
III lupus nephritis, while the highest mean level of anti-histone
antibodies was in patients with grade II lupus nephritis
(Table 4).
Furthermore, an anti-chromatin antibody level of 37.5 U/L
was postulated as a cutoff point with 100% sensitivity, and
66.7% speciﬁcity. Regarding anti-histone antibodies, a level
of 7.1 U/L was the cutoff point that showed 100% sensitivity,
and 53.3% speciﬁcity.4. Discussion
Systemic lupus erythematosus is an autoimmune disease char-
acterized by the production of antibodies against various cell
components leading to a spectrum of clinical ﬁndings ranging
from lesions conﬁned to the skin to multisystem organ involve-
ment [14]. The etiology of SLE remains largely unknown and is
multifactorial. Several factors in the environment can con-
tribute to onset and relapses of SLE. Mainly chemical and
physical factors have been studied in SLE, whereas social
and behavioral aspects have been less investigated [15].
Abnormalities in immune regulation are thought to be the
consequence of a loss of self-tolerance in affected patients,
leading to an autoimmune response with abnormal cellular
Table 1 Characteristics of systemic lupus erythematosus (SLE) patients (Group A).
Parameter SLE patients (Group A) (N= 60)
Age (years), mean ± SD (range) 29.3 ± 7.5 (17–50)
Age of onset (years), mean ± SD (range) 23.4 ± 7.4 (16–49)
Disease duration (years), mean ± SD (range) 6.1 ± 3.9 (1–18)
Clinical manifestations N (%)
Constitutional
Fever 45 (75)
Fatigue 43 (71.7)
Weight loss 27 (45)
Musculoskeletal
Arthralgia 46 (76.7)
Arthritis 51 (85)
Myositis 1 (1.7)
Mucocutaneous
Photosensitivity 44 (73.3)
Malar rash 51 (85)
Alopecia 52 (86.7)
Oral ulcer 52 (86.7)
Discoid lesion 10 (16.7)
Cardiopulmonary 40 (66.7)
Pleurisy and pleural eﬀusion 31 (51.7)
Pericarditis and pericardial eﬀusion 14 (23.3)
Interstitial pneumonitis 1 (1.7)
Pulmonary hypertension 31 (51.7)
Gastrointestinal
Hepatomegaly 4 (6.7)
Splenomegaly 1 (1.7)
Ascites 21 (35)
CNS manifestations
Cognitive impairment 3 (5)
Seizures 9 (15)
Psychosis 5 (8.3)
Stroke 2 (3.3)
Mononeuritis multiplex 9 (15)
Transverse myelitis 2 (3.3)
Peripheral neuropathy 1 (1.7)
Renal aﬀection 48 (80)
Vascular manifestations
Vasculitis 21 (35)
Nail fold capillary vasculitis 2 (3.3)
Cutaneous vasculitis 2 (3.3)
Retinal vasculitis 2 (3.3)
Deep venous thrombosis 28 (46.7)
Hematologic 24 (40)
Anemia 9 (15)
Leukopenia 9 (15)
Thrombocytopenia 9 (15)
SLEDAI, mean ± SD (range) 26.8 ± 9.3 (9–47)
Laboratory characteristics Mean ± SD (range)
Erythrocyte sedimentation rate (mm/1st hour) 51.8 ± 37.95 (5–170)
Hemoglobin (g/dL) 11.4 ± 1.96 (6.8–16.6)
Total leukocytic count (·103/mm3) 8.1 ± 3.7 (2.2–19.2)
Platelets (·103/mm3) 262.3 ± 125.1 (76–941)
Alanine transaminase ALT (U/L) 25.2 ± 27.9 (6–202)
Aspartate transaminase AST (U/L) 23.8 ± 14.1 (6–85)
Urea (mg/dL) 49.4 ± 58.4 (7–136)
Creatinine (mg/dL) 1.4 ± 3.5 (0.2–6.5)
Immune proﬁle, N (%)
ANA positivity 60 (100)
Anti-dsDNA positivity 53 (87)
Anti-cardiolipin positivity 20 (32)
Anti-Sm positivity 11 (17)
Anti-Ro positivity 5 (8.3)
Anti-La positivity 3 (5)
C3, mean ± SD (range) 66.7 ± 44.95 (0.03–158)
C4, mean ± SD (range) 15.8 ± 11.8 (0.06–35)
Drug intake N (%)
Steroids 60 (100)
Hydroxychloroquine (HCQ) 52 (86.7)
Azathioprine (Immuran) 44 (73.3)
Cyclophosphamide (Endoxan) 21 (35)
Mycophenolate mofetil (Cellcept) 3 (5)
CNS, central nervous system; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; Anti-dsDNA, anti-double strand deoxyri-
bonucleic acid; ANA, anti-nuclear antibodies; C3, complement factor 3; C4, complement factor 4.
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Table 2 A comparison between the mean levels of anti-chromatin and anti-histone antibodies among Group (A) SLE patients with
different manifestations.
Variable No. Anti-chromatin Abs Anti-histone Abs
Mean ± SD p Mean ± SD p
Arthritis Yes 51 103.1 ± 24.96 0.62 17.96 ± 7.6 0.98
No 9 102.5 ± 14.9 16.8 ± 5.2
Vasculitis Yes 27 99.4 ± 27.3 0.499 17.99 ± 7.6 0.99
No 33 105.98 ± 20.1 17.6 ± 7.1
Serositis Yes 41 100.4 ± 22.3 0.07 17.4 ± 5.95 0.89
No 19 108.7 ± 25.98 18.9 ± 9.6
CNS Yes 21 103.4 ± 30.02 0.57 17.9 ± 5.4 0.52
No 39 102.8 ± 19.8 17.7 ± 8.1
GIT Yes 31 103.04 ± 22.8 0.96 18.8 ± 7.0 0.16
No 29 103.0 ± 24.9 16.7 ± 7.4
Hematological Yes 28 110.98 ± 18.5 0.01* 18.5 ± 6.8 0.22
No 32 96.1 ± 25.7 17.1 ± 7.7
Renal Yes 48 104.9 ± 21.7 0.39 18.6 ± 7.4 0.09
No 12 95.6 ± 30.1 14.7 ± 5.6
CNS, central nervous system; GIT, gastrointestinal tract.
* Statistically signiﬁcant difference.
Figure 1 The mean levels of anti-chromatin and anti-histone antibodies in SLE patients (Group A) and healthy Controls (Group B).
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ent auto-antibodies have been associated with SLE in the past,
most notably anti-nuclear antibodies (ANA) and anti-double-
stranded DNA (anti-dsDNA) antibodies, the most relevant
tests in diagnosing SLE. Patients with SLE have been shown
to have elevated antibody levels in 50–80% of cases, correlat-
ing with disease activity [6]. In the present study the ANA anti-
bodies were positive in 100% of the cases and the anti-dsDNA
in 87%. In other studies on Egyptian SLE patients, the ANA
was positive in 93–100% [17–19] while the anti-dsDNA was
positive in 64–67% [17,18].
Additional antibodies with potential pathogenic and diag-
nostic relevance have been recognized in SLE [6]. Anti-chro-
matin antibodies, also referred to as antinucleosome
antibodies, are directed against a major autoantigen in SLE,
namely nucleosomes (nuclear histone-DNA complexes). Sever-
al studies have noted a prevalence of anti-chromatin antibodies
in SLE patients of 48–80% [20]. Anti-histone antibodies havebeen detected in 18–53% of patients with SLE, and up to 95%
of patients with drug-induced lupus [21].
In our study, SLE patients had a mean age of 29.3 ±
7.5 years, and mean disease duration of 6.1 ± 3.9 years. Sha-
bana and coworkers studied SLE patients with a mean age
of 25 ± 9.3 years which is close to the age of our patients;
however they had shorter disease duration of 3.3 ± 3.2 years
[22]. On the other hand, SLE patients studied by Souza et al.
were older with a mean age of 35.1 ± 11.9 years [14]. Further-
more, our patients had a higher SLE Disease Activity Index
(SLEDAI) with a mean of 26.8 ± 9.3 as compared to those
of Souza et al. with a mean of 16.5 ± 9.6 [14].
In our study renal affection was present in 80% of patients,
alopecia and oral ulcers in 86.7%, arthritis in 85%, and cardio-
pulmonary affection in 66.7%. However, Shabana and
coworkers found renal affection in 36.9% of SLE patients,
malar rash in 60.5%, alopecia in 57.9%, cardiac involvement
in 5.3% and pulmonary affection in 18.4% [22]. Accordingly,
Table 3 Correlation between the mean levels of anti-chro-
matin and anti-histone antibodies among Group (A) SLE
patients with various variables.
Variable Antibodies
Anti-chromatin Anti-histone
Age r 0.04 0.07
p 0.74 0.61
Age of onset r 0.11 0.001
p 0.38 0.99
Duration r 0.14 0.08
p 0.27 0.52
SLEDAI r 0.06 0.02
p 0.65 0.90
ESR r 0.197 0.05
p 0.13 0.71
Hemoglobin r 0.39 0.09
p 0.002* 0.49
TLC r 0.19 0.11
p 0.16 0.39
Platelets r 0.004 0.09
p 0.97 0.496
FBG r 0.17 0.07
p 0.20 0.58
ALT r 0.095 0.04
p 0.47 0.75
AST r 0.13 0.13
p 0.33 0.34
Albumin r 0.03 0.01
p 0.83 0.97
Urea r 0.10 0.20
p 0.45 0.12
Creatinine r 0.04 0.15
p 0.74 0.26
24hr Urinary proteins r 0.07 0.09
p 0.59 0.49
C3 r 0.04 0.08
p 0.77 0.55
C4 r 0.01 0.10
p 0.94 0.43
Drug intake
Steroid Dose r 0.16 0.06
p 0.22 0.64
Duration r 0.26 0.14
p 0.044* 0.27
HCQ Dose r 0.29 0.04
p 0.037* 0.77
Duration r 0.28 0.08
p 0.049* 0.59
Azathioprine Dose r 0.16 0.15
p 0.30 0.32
Duration r 0.19 0.07
p 0.23 0.67
Cyclophosphamide Dose r 0.19 0.09
p 0.39 0.68
Duration r 0.13 0.02
p 0.57 0.93
SLEDAI, systemic lupus erythematosus disease activity index;
ESR, erythrocyte sedimentation rate; TLC, total leukocytic count;
FBS, fasting blood sugar; ALT, alanine transaminase; AST,
aspartate transaminase; C, complement; HCQ,
hydroxychloroquine.
* Statistically signiﬁcant difference.
Table 4 Comparison between serum levels of both anti-
chromatin and anti-histone antibodies among SLE patients
with various grades of renal involvement.
Grade of renal involvement No. Antibodies
mean ± SD (range) Anti-chromatin Anti-histone
Grade II 8 101.5 ± 25.6 24.7 ± 12.7
(65.3–142.5) (9.02–42.1)
Grade III 10 116.6 ± 12.4 16.9 ± 3.8
(98.2–137.2) (10.7–24.3)
Grade IV 22 105.9 ± 21.5 16.9 ± 5.3
(55.3–136.6) (8.6–28.4)
Grade V 2 104.5 ± 7.3 18.3 ± 14.1
(99.3–109.6) (8.3–28.3)
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loskeletal, renal and cardio-pulmonary manifestations than
the study of Shabana et al. In another study on Egyptian
SLE patients, renal involvement was present in 95%, mucocu-
taneous manifestations in 72.5%, arthritis in 67.5% and car-
diopulmonary involvement in 30.5% [17].
Our data showed that the level of anti-chromatin antibodies
was signiﬁcantly higher in SLE patients with hematological
manifestations as compared to those without (p= 0.01), while
it did not show a statistically signiﬁcant difference between
those with arthritis, vasculitis, serositis, CNS, gastrointestinal,
or renal affection and those without. On the contrary, the
study of Shabana et al. showed that the levels of anti-chromat-
in antibody were signiﬁcantly higher in SLE patients with
arthritis, malar rash, oral ulcer and pulmonary affection than
those without (p< 0.05) [22]. Additionally, Saisoong et al.
showed a signiﬁcantly higher level of anti-chromatin antibody
patients with lupus nephritis (p= 0.03) [23]. In another study
on Egyptian SLE patients, serum levels of anti-nucleosome
antibodies were associated with active lupus disease and corre-
lated with the degree of renal affection [24]. These discrepan-
cies could be attributed either to the larger group of studied
patients, different selection criteria, or different technique used
for antibody detection. Regarding anti-histone antibody, our
ﬁndings showed that its level did not differ signiﬁcantly in
SLE patients with arthritis, vasculitis, serositis, CNS, gastroin-
testinal, hematological manifestations, or renal affection as
compared to those without. While Shabana et al. showed that
the level of anti-histone antibodies was signiﬁcantly higher in
patients with fatigue only, and not with any other clinical
manifestations [22].
Among all laboratory ﬁndings in our study, only hemoglo-
bin concentration showed a statistically signiﬁcant negative
correlation with anti-chromatin antibodies (r= 0.395,
p= 0.002).
In the study of Shabana and coworkers, SLEDAI scores of
SLE patients positively correlated with serum levels of anti-
chromatin antibodies (p< 0.001) but not with the serum levels
of anti-histone antibodies; no signiﬁcant correlations were
observed between anti-chromatin and anti-histone antibodies
and any of the hematological parameters in their SLE patients
[22]. Also in disarrangement with our results Saisoong et al.
showed a correlation between both anti-chromatin and anti-
DNA antibody levels and disease activities (r= 0.33,
Levels of anti-chromatin and anti-histone antibodies in patients with SLE 103p= 0.007 and r= 0.37, p= 0.002 respectively) [23]. In our
patients anti-chromatin and anti-histone antibodies did not
correlate with SLEDAI, ESR or with platelets. This could be
attributed to the effect of medications on disease activity of
our patients. As we showed there was a signiﬁcant negative
correlation of anti-chromatin antibodies and steroid duration
and HCQ dose and duration. This can have therapeutic impli-
cations on these antibodies.
Saisoong et al. reported that no correlation was observed
between antinucleosome antibody activity and C4 levels [23].
Similarly, in our study we did not observe a correlation
between anti-chromatin and anti-histone antibodies and C3
or C4 levels.
In our study 42 lupus nephritis patients performed renal
biopsy (70%), the highest mean of anti-chromatin antibodies
was in lupus nephritis grade III patients, while the highest
mean of anti-histone antibodies was in lupus nephritis grade
II patients. There was no statistical signiﬁcant difference
between the mean level of anti-chromatin and anti-histone
antibodies in patients with and without renal affection
(p= 0.39 and p= 0.09, respectively). In agreement with our
results, Shabana et al., showed no signiﬁcant statistical differ-
ence between serum levels of anti-histone antibodies in patients
with and without renal involvement and no signiﬁcant correla-
tion between these antibodies and renal biopsy class. However,
their results are different regarding anti-chromatin antibodies
which were signiﬁcantly higher (p< 0.01) in patients with,
than in those without nephritis. Also in their study, there
was a signiﬁcant correlation between serum levels of anti-chro-
matin antibodies (p< 0.01) and World Health Organization
(WHO) renal biopsy classes [22]. Contrary to our results, Puto-
va et al. showed statistical signiﬁcant higher serum levels of
anti-nucleosome antibodies in patients with lupus nephritis.
This could be related to the different patient selection and
racial differences [25]. Similar to our results, many researchers
failed to show association between both anti-chromatin and
anti-histone antibodies and lupus nephritis [26–28].
In our study, anti-chromatin antibodies had 100% sensi-
tivity and 66.7% speciﬁcity at the cutoff point of 37.5 U/L
while anti-histone antibodies had a 100% sensitivity and
53.3% speciﬁcity at the cutoff point 7.1 U/L. The study of
Schett et al. had a sensitivity of anti-chromatin antibodies of
48% and speciﬁcity of 95%, while sensitivity of anti-histone
antibodies was 45% and speciﬁcity was 98% [27]. In the study
of Bose et al. the anti-chromatin antibody sensitivity was
62.4% and the speciﬁcity was 91.5% [29]. A systematic review
and metanalysis showed that the overall sensitivity of the anti-
nucleosome assay was 61% and the speciﬁcity 94% [8]. In the
present study the sensitivity was higher and the speciﬁcity low-
er than the other studies. In the study of Shabana et al., anti-
chromatin antibody sensitivity was 89.5% and speciﬁcity
92.1%, while anti-histone antibodies showed a sensitivity of
80% and speciﬁcity of 82.2% [22]. These values were also simi-
lar to what was reported by Go´mez-Puerta et al. [30]. Our
results are close to these authors as regards sensitivity but
not speciﬁcity. This could be attributed to the techniques
and method used in our study to detect these antibodies and
to the different cutoff points used.
The results of the present study emphasize the clinical ben-
eﬁts of anti-chromatin and anti-histone antibodies. Their
detection could be more applicable for the diagnosis of SLE
especially in cases with negative ANA, as they are highlysensitive and speciﬁc. The effect of drugs on the presence of
anti-chromatin and anti-histone antibodies could be used for
therapeutic purposes. Further large-scale studies are required
for showing their effects.
In conclusion, the results of our study indicate that: anti-
chromatin and anti-histone antibodies are both sensitive and
speciﬁc for SLE and could be a useful addition to the labora-
tory tests that can help in the diagnosis of SLE. Determination
of anti-chromatin antibodies could be a promising useful para-
meter to assess the effect of drugs on disease activity status.
Furthermore, increased titer of anti-chromatin antibodies
appears to be a sensitive marker for identifying patients with
hematological manifestations.Conﬂict of interest
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